Clincosm LogoSign in Get a demo

SCB-2019 as COVID-19 Vaccine

Sponsor
Clover Biopharmaceuticals AUS Pty Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT04405908
Collaborator
(none)
166
Enrollment
1
Location
27
Arms
17.6
Actual Duration (Months)
9.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a randomized, double blind, placebo controlled, first-in-human (FIH) study to assess safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels, administered as 2 injections IM in healthy subjects. Each study vaccine dose level will be evaluated with and without adjuvant.

Condition or Disease Intervention/Treatment Phase
  • Biological: SCB-2019
  • Biological: SCB-2019 with AS03 adjuvant
  • Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
  • Biological: SCB-2019 with Alum adjuvant
 Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
166 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.
Actual Study Start Date :
Jun 19, 2020
Actual Primary Completion Date :
Oct 20, 2021
Actual Study Completion Date :
Dec 8, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Adult Group 1

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg.

Biological: SCB-2019
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
Placebo Comparator: Adult Group 2

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Adult Group 3

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: Adult Group 4

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg .

Biological: SCB-2019
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
Placebo Comparator: Adult Group 5

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Adult Group 6

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: Adult Group 7

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg .

Biological: SCB-2019
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
Placebo Comparator: Adult Group 8

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Adult Group 9

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: Elderly Group 10

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Elderly Group 11

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: Elderly Group 12

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Elderly Group 13

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: Elderly Group 14

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Elderly Group 15

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: SARS-CoV-2 Seropositive Group 16

SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg.

Biological: SCB-2019
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
Placebo Comparator: SARS-CoV-2 Seropositive Group 17

SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: SARS-CoV-2 Seropositive Group 18

SARS-CoV-2 Seropositive subjects receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: Adjuvant Dose Modification: Adult Group 19

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Adjuvant Dose Modification: Adult Group 20

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: Adjuvant Dose Modification: Elderly Group 21

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Adjuvant Dose Modification: Elderly Group 22

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: Alum Only Adjuvant Group 23

Subjects receive SCB-2019 9 µg with Alum adjuvant only.

Biological: SCB-2019 with Alum adjuvant
SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
Placebo Comparator: Dose Expansion Phase: Adult Group 24

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Dose Expansion Phase: Adult Group 25

Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Placebo Comparator: Dose Expansion Phase: Elderly Group 26

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.

Biological: SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Placebo Comparator: Dose Expansion Phase: Elderly Group 27

Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.

Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.

Outcome Measures

Primary Outcome Measures

  1. Incidence of solicited adverse events (AEs) after vaccination [7 days after the first or second vaccination.]

    To evaluate the safety and reactogenicity profile of adjuvanted and unadjuvanted SCB-2019 in adult and elderly , when administered as 2 intramuscular doses.

  2. Incidence of unsolicited AEs after vaccination [Day 1 to Day 50]

    To evaluate the safety and reactogenicity profile of adjuvanted and unadjuvanted SCB-2019 in adult and elderly , when administered as 2 intramuscular doses.

  3. Mean change from Baseline in safety laboratory measures (include hematology, coagulation panel, and serum chemistry) [Day 1 to Day 50]

    To evaluate the safety and reactogenicity profile of adjuvanted and unadjuvanted SCB-2019 in adult and elderly , when administered as 2 intramuscular doses.

  4. Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs) [Day 1 to Day 184]

    To evaluate the safety and reactogenicity profile of adjuvanted and unadjuvanted SCB-2019 in adult and elderly , when administered as 2 intramuscular doses.

  5. As assessed by serum anti-SCB-2019 IgG antibody titers [Day 1 to Day 184]

    Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

Secondary Outcome Measures

  1. Immunogenicity( serum anti SARS-CoV-2 neutralizing antibody titers (ACE2 receptor-based) ) [Day 1 to Day 184]

    Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

  2. Immunogenicity(serum anti SARS-CoV-2 neutralizing antibody titers (cell based) ) [Day 1 to Day 184]

    Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

  3. Immunogenicity(serum anti SARS-CoV-2 whole virus antibody titers) [Day 1 to Day 184]

    Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

  4. Antibody kinetics of each SCB 2019 vaccine formulation after first and second doses [Day 1 to Day 184]

    Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  1. Healthy adult male or females, ≥18 years of age at Screening:

  2. For the adult group: 18 to 54 years, inclusive, and

  3. For the elderly group: 55 to 75 years, inclusive.

  4. Individuals who are willing and able to give an informed consent, prior to Screening.

  5. Individuals who are able to comply with study requirements.

  6. Female subjects are eligible to participate in the study if not pregnant, not breastfeeding, and at least 1 of the following criteria apply:

  7. Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test prior to each vaccination. They must be using a highly effective licensed method of birth control for 30 days prior to the first dose of the study vaccine/placebo and must agree to continue such precautions during the study until 60 days after the second dose of the study vaccine/placebo.

  8. Women not of childbearing potential, defined as surgically sterile (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal (no menses for 12 months and follicle-stimulating hormone [FSH] in the postmenopausal range).

  9. Male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 90 days after the second dose of the study vaccine/placebo and also refrain from donating sperm during this period.

  10. General good health based on medical history, physical examination, cardiac health evaluation, and clinical laboratory evaluations. Participants in the elderly population who have medically stable, well-controlled co-morbidities may be enrolled at the discretion of the Investigator.

All clinical laboratory values should be within normal reference ranges unless confirmed by Investigator or delegate as not clinically significant. One repeat evaluation of electrocardiogram (ECG), and clinical laboratory tests will be permitted, at the discretion of the Investigator.

  1. Individuals agree to avoid strenuous exercise from Screening to Day 50.
For the SARS-CoV-2 seropositive treatment group only (Treatment Groups 16 to 18):

  1. Serological or ELISA confirmation of SARS-CoV-2;

  2. No history of severe SARS-CoV-2 symptoms;

  3. No SARS-CoV-2 symptoms at the time of the screening .

Exclusion Criteria:

  1. Individuals with any positive test for SARS-CoV-2 infection, including but not limited to RT-PCR, at Screening (excluding the SARS-CoV-2 seropositive treatment group [Treatment Groups 16 to 18]).

  2. Individuals with positive serology test results for SARS-CoV-2 at Screening (excluding the SARS-CoV-2 seropositive treatment group [Treatment Groups 16 to 18]).

  3. Individuals with behavioral or cognitive impairment in the opinion of the Investigator.

  4. Individuals with any progressive or severe neurologic disorder, seizure disorder, or history of Guillian-Barré syndrome.

  5. Individuals who are not able to comprehend and to follow all required study procedures for the whole period of the study.

  6. Individuals with known or suspected impairment of the immune system, such as:

  7. Use of systemic (oral or parenteral) corticosteroids for ≥14 consecutive days within 60 days prior to Day 1. Use of inhaled, intranasal, or topical corticosteroids is allowed.Note: Systemic (oral or parenteral) corticosteroids are also prohibited for 3 weeks after the second dose of the study vaccine/placebo.

  8. Receipt of cancer chemotherapy within 5 years prior to Day 1.

  9. Receipt of immunostimulants or immunosuppressants within 60 days prior to Day 1.

  10. Known HIV or acquired immune deficiency syndrome (AIDS).

  11. Subjects with active or prior documented autoimmune disorder (such as potential immune-mediated diseases [pIMDs]).

  12. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Day 1 or planned during the full length of the study.

  13. Positive serology test results for hepatitis C virus antibody, HIV antibody, and/or hepatitis B virus surface antigen at Screening.

  14. Individuals who are pregnant or breastfeeding.

  15. Individuals who are allergic to any of the study vaccine/placebo components as outlined in the current SCB 2019 IB.

  16. Individuals who have had a malignancy (excluding nonmelanotic skin cancer) or lymphoproliferative disorder within the past 5 years from the date of first administration of the study vaccine/placebo (Day 1).

  17. Individuals who have received any other investigational product within 30 days prior to Day 1 or intent to participate in another clinical study at any time during the conduct of this study.

  18. Individuals with a body temperature ≥38.0 °C (≥100.4 °F) or any acute illness within 3 days of intended study vaccination.

  19. Individuals who have a previous confirmed or suspected illness caused by coronaviruses, SARS-CoV-1, SARS-CoV-2, and Middle East Respiratory Syndrome (MERS)-CoV (excluding the SARS-CoV-2 seropositive treatment group [Treatment Groups 16 to 18]).

  20. Individuals who have received any prior vaccine against a coronavirus, including but not limited to SARS-CoV, SARS-CoV-2, MERS-CoV.

  21. Individuals who have received any other licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this study or who are planning to receive any vaccine within 28 days (before or after) the study vaccine/placebos, with the exception of the seasonal influenza vaccine.

  22. Presence of uncontrolled chronic pulmonary, cardiovascular, renal, hepatic, neurologic, hematologic or metabolic (including diabetes mellitus) disorders, which would include the potential subject in a high-risk category for SARS CoV 2 infection and/or its complications.

  23. Individuals with known bleeding diathesis.

  24. Individuals with a body mass index <18.5 kg/m2 or >35.0 kg/m2.

  25. Individuals with a history of drug or alcohol abuse within the past 2 years.

  26. Individuals with a history of anaphylaxis or angioedema including but not limited to history of anaphylaxis after any vaccine.

  27. Individuals with any condition that, in the opinion of the Investigator, would interfere with the primary study objectives or pose additional subject risk.

  28. Individuals who are research staff involved with the clinical study or family/household members of research staff.

  29. Individuals must not have donated blood for 2 months prior to Day 1 and must agree to not donate blood for 6 months post Day 1 (receipt of first dose of study vaccine).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Linear Clinical Research Ltd Nedlands Western Australia Australia 6009

Sponsors and Collaborators

  • Clover Biopharmaceuticals AUS Pty Ltd

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Clover Biopharmaceuticals AUS Pty Ltd
ClinicalTrials.gov Identifier:
NCT04405908
Other Study ID Numbers:
  • CLO-SCB-2019-001
First Posted:
May 28, 2020
Last Update Posted:
Feb 18, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
COVID-19
Aluminum Hydroxide
Aluminum sulfate
1018 oligonucleotide

Study Results

No Results Posted as of Feb 18, 2022